pegylated interferon alpha-2a (pegIFN)

DRUG2 trials

Sponsors

AbbVie (prior sponsor, Abbott), Janssen R&D Ireland

Conditions

Chronic Hepatitis C

Phase 2

A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study

CompletedNCT01609933

AbbVie (prior sponsor, Abbott)Chronic Hepatitis C

Start: 2012-12-18End: 2017-05-03Updated: 2018-06-19

A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus

CompletedNCT01724086

Janssen R&D IrelandChronic Hepatitis C

Start: 2012-10-31End: 2014-12-31Updated: 2016-01-11

Related Papers

Ombitasvir, paritaprevir, and ritonavir with peginterferon-α2a plus ribavirin in treatment-experienced patients with chronic hepatitis C virus genotype 1 infection.

2019-02-13

Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845

Virology Journal2017-05-314 citations

Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection.

2017-02-104 citations